Investigating the hydrate conversion propensity of different etoricoxib lots

Journal of Pharmaceutical Sciences

Volumn 95, Issue 1, 2006, Pages 56-69

  Dalton, Chad R ^a   Clas, Sophie Dorothée ^a   Singh, Jaspal ^a   Khougaz, Karine ^a   Bilbeisi, Rana ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Amorphous; Compression; Hydrate; Lot dependency; Milling; Particle size; Polymorphism; Raman spectroscopy; X ray powder diffractometry

Indexed keywords

BULKING AGENT; ETORICOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDINE DERIVATIVE; SULFONE;

ARTICLE; DRUG FORMULATION; DRUG PURITY; DRUG SCREENING; DRUG STABILITY; HYDRATION; PARTICLE SIZE; QUALITATIVE ANALYSIS; RAMAN SPECTROMETRY; SURFACE PROPERTY; X RAY POWDER DIFFRACTION; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL SCANNING CALORIMETRY; SCANNING ELECTRON MICROSCOPY; THERMOGRAVIMETRY; X RAY DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE INHIBITORS; DRUG COMPOUNDING; DRUG STABILITY; MICROSCOPY, ELECTRON, SCANNING; PYRIDINES; SPECTRUM ANALYSIS, RAMAN; SULFONES; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 33645243995     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20499     Document Type: Article

References (27)

1. Hargrove JT, Maxson WS, Wentz AC. 1989. Absorption of oral progesterone is influenced by vehicle and particle size. Am J Obstet Gynecol 161:948-951.
2. Phadnis V, Suryanarayanan R. 1997. Polymorphism in anhydrous theophylline -Implications in the rate of theophylline tablets. J Pharm Sci 86:1256-1261.
3. Vippagunta SR, Brittain HG, Grant DJW. 2001. Crystalline solids. Adv Drug Del Rev 48:3-26.
4. Giron D, Goldbronn C, Mutz M, Pfeffer S, Piechon P, Schwab P. 2002. Solid state characterization of pharmaceutical hydrates. J Therm Anal Cal 68:453-465.
5. Khankari RK, Grant DJW. 1995. Pharmaceutical hydrates. Int J Pharm 248:61-79.
6. Buckton G. 1995. Surface characterization: Understanding sources of variability in the production and use of pharmaceuticals. J Pharm Pharmacy 47:265-275.
7. Buckton G. 1997. Characterization of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv Drug Deliv Rev 26:17-27.
8. Ticehurst MD, Rowe RC, York P. 1994. Determination of the surface properties of two batches of salbutamol sulphate by inverse gas chromatography. Int J Pharm 111:241-249.
9. Ticehurst MD, Rowe RC, York P, Rowe RC, Dwivedi SK. 1996. Characterisation of the surface properties of a lactose monohydrate with inverse gas chromatography, used to detect batch variation. Int J Pharm 141:93-99.
10. Grimsey JM, Feely JC, York P. 2002. Analysis of the surface energy of pharmaceutical powders by inverse gas chromatography. J Pharm Sci 91:571-583.
11. Clas S-D. 2003. The importance of characterizing the crystal form of the drug substance during drug development. Curr Opin Drug Discov Dev 6:550-560.
12. Crocker LS, McCauley JA. 1995. Comparison of the crystallinity of Imipenem samples by X-ray diffraction of amorphous material. J Pharm Sci 84:226-227.
13. Hancock BC, Christensen K, Shamblin SL. 1998. Estimating the critical molecular mobility temperature (Tk) of amorphous pharmaceuticals. Pharm Res 15:1649-1651.
14. Saklatvala R, Royall PG, Craig DQM. 1999. The detection of amorphous material in a nominally crystalline drug using modulated temperature DSC - A case study. Int J Pharm 192:55-62.
15. Buckton G, Darcy P. 1995. The use of gravimetric studies to assess the degree of crystallinity of predominantly crystalline powders. Int J Pharm 123:265-271.
16. Ticehurst MD, Rowe RC, York P, Dwivedi SK. 1996. Characterisation of the surface properties of α-lactose monohydrate with inverse gas chromatography used to detect batch variation. Int J Pharm 141:93-99.
17. Giron D. 1999. Thermal analysis, microcalorimetry, and combined techniques for the study of pharmaceuticals. J Therm Anal Calorim 56:1285-1304.
18. Yu L. 2001. Amorphous pharmaceutical solids: Preparation characterization and stabilization. Adv Drug Deliv Rev 48:27-42.
19. Tishmack PA, Bugay DE, Byrn SR. 2003. Solid-state nuclear magnetic resonance spectroscopy-pharmaceutical applications. J Pharm Sci 92:441-474.
20. Buckton G, Dove JW, Davies P. 1999. Isothermal microcalorimetry and inverse phase gas chromatography to study small changes in powder surface properties. Int J Pharm 193:13-19.
21. Bauer J, Spanton S, Henry R, Quick J, Dziki W, Porter W, Morris J. 2001. Ritonavir: An extraordinary example of conformational polymorphism. Pharm Res 18:859-866.
22. Crocker LS, Ge Z, Abrahim A, Hartman R, Xu J. 2003. An etoricoxib phase diagram: Hemihydrate and anhydrate. Org Process Res Dev 7:958-961.
23. O'Shea P, Tillyer RD, Wang X, Clas S-D, Dalton C, 2000. Synthesis of 4-[(5-substituted or unsubstituted phenyl)-3-substituted-1H-pyrazol-1-Y1] benzenesulfonamides. US Patent 6,150,534.
24. Clas S-D, O'Shea P, Dalton C, Crocker LS, McCauley JA, Tillyer RD, Davis I, 2002. Polymorphic, amorphous and hydrated forms of 5-chloro-6′-methyl- 3-[4-(methylsulfonyl)phenyl]-2,3′-bipyridine. US Patent 6,441,002.
25. Clas S-D, Dalton CR, Hancock BC. 2002. Calorimetry in pharmaceutical research and development. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology, Vol. 1, 2nd edn. New York: Marcel Dekker, Inc. pp 289-301.
26. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharma Sci 86:1-12.
27. Blagden N, Davey RJ, Rowe R, Roberts R. 1998. Disappearing polymorphs and the role of reaction by-products: The case of sulphathiazole. Int J Pharm 172:169-177.